AstraZeneca PLC (LSE:AZN) is set to see a sales boost from new lung cancer treatments, according to UBS analysts, after the pharmaceuticals firm updated on two treatments on Monday. UBS anticipated peak sales of US$2.5 billion for Dato-DXd, which saw its application accepted by the US Food and Drug Administration on Monday. Tagrisso, approved by the administration for use alongside chemotherapy in lung cancer patients, was forecast to bring incremental peak sales of US$500 million, meanwhile. AstraZeneca un ...